Atossa Genetics EPS - Earnings per Share 2012-2024 | ATOS
Atossa Genetics eps - earnings per share from 2012 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Atossa Genetics Annual EPS | |
|---|---|
| 2024 | $-0.20 |
| 2023 | $-0.24 |
| 2022 | $-0.21 |
| 2021 | $-0.18 |
| 2020 | $-1.97 |
| 2019 | $-2.03 |
| 2018 | $-5.50 |
| 2017 | $-10.97 |
| 2016 | $-25.93 |
| 2015 | $-99.76 |
| 2014 | $-109.79 |
| 2013 | $-125.99 |
| 2012 | $-73.79 |
| 2011 | $-68.39 |
| Atossa Genetics Quarterly EPS | |
|---|---|
| 2024-12-31 | $-0.04 |
| 2024-09-30 | $-0.06 |
| 2024-06-30 | $-0.05 |
| 2024-03-31 | $-0.05 |
| 2023-12-31 | $-0.06 |
| 2023-09-30 | $-0.05 |
| 2023-06-30 | $-0.08 |
| 2023-03-31 | $-0.05 |
| 2022-12-31 | $-0.06 |
| 2022-09-30 | $-0.06 |
| 2022-06-30 | $-0.05 |
| 2022-03-31 | $-0.04 |
| 2021-12-31 | $-0.04 |
| 2021-09-30 | $-0.04 |
| 2021-06-30 | $-0.06 |
| 2021-03-31 | $-0.04 |
| 2020-12-31 | $-0.88 |
| 2020-09-30 | $-0.34 |
| 2020-06-30 | $-0.43 |
| 2020-03-31 | $-0.32 |
| 2019-12-31 | $-0.25 |
| 2019-09-30 | $-0.36 |
| 2019-06-30 | $-0.80 |
| 2019-03-31 | $-0.62 |
| 2018-12-31 | $8.70 |
| 2018-09-30 | $-0.64 |
| 2018-06-30 | $-5.08 |
| 2018-03-31 | $-8.48 |
| 2017-12-31 | $4.26 |
| 2017-09-30 | $-2.11 |
| 2017-06-30 | $-7.72 |
| 2017-03-31 | $-5.40 |
| 2016-12-31 | $-6.96 |
| 2016-09-30 | $0.84 |
| 2016-06-30 | $-8.04 |
| 2016-03-31 | $-11.77 |
| 2015-12-31 | $-28.47 |
| 2015-09-30 | $-28.09 |
| 2015-06-30 | $-19.80 |
| 2015-03-31 | $-23.40 |
| 2014-12-31 | $-45.00 |
| 2014-09-30 | $-23.40 |
| 2014-06-30 | $-23.40 |
| 2014-03-31 | $-18.00 |
| 2013-12-31 | $-30.60 |
| 2013-09-30 | $-39.60 |
| 2013-06-30 | $-30.60 |
| 2013-03-31 | $-25.20 |
| 2012-12-31 | $-21.60 |
| 2012-09-30 | $-18.00 |
| 2012-06-30 | $-18.00 |
| 2012-03-31 | $-16.20 |
| 2011-12-31 | $0.00 |
| 2011-09-30 | $-19.80 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.110B | $0.000B |
| Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA. | |||